Convert Pharmaceuticals SA
The score of Convert Pharmaceuticals shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -9 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Convert Pharmaceuticals's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −629,343 € | ||||
| Equity | −841,823 € | ||||
| Cash | 158,318 € | ||||
| EBITDA | −248,104 € | ||||
| Total assets | 941,204 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 17 Jun 2026
- Year ended 31 Dec 2024filed on 26 Jun 2025
- Year ended 31 Dec 2023filed on 06 Jun 2024
- Year ended 31 Dec 2022filed on 08 Jun 2023
- Year ended 31 Dec 2021filed on 12 Jul 2022
Convert Pharmaceuticals's financial analysis
- Solvency-89.4%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Convert Pharmaceuticals
Convert Pharmaceuticals's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0671.828.631
- VAT number
- BE0671828631
- Peppol
- Registered · 0208:0671828631 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 24 Feb 2017
- Registered office
- 4000 Liège
- Latest accounts
- 2025 · filed on 17 Jun 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Convert Pharmaceuticals (SA) has been based in Liège since 2017, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net loss of 629,343 € and equity of −841,823 €; its revenue is not published. Its solvency stands at -89.4%, below the median of its sector (57.9%).
Companies similar to Convert Pharmaceuticals
Companies in the same business, of comparable size and area, outside its group.
- MSI-Dfat EU Research and experimental development on natural sciences and engineering Jodoigne · balance sheet €1.08m
- Emicap Research and experimental development on natural sciences and engineering Kortrijk · balance sheet 941,206 €
- Gynaia Belgium Research and experimental development on natural sciences and engineering Leuven · balance sheet €1.00m
- Afems Research and experimental development on natural sciences and engineering Auderghem · balance sheet 863,868 €
- Tavira Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet 863,682 €
- Jacques Coenen Group Research and experimental development on natural sciences and engineering Overijse · balance sheet €1.26m
- Digital Dental Design Robotics Research and experimental development on natural sciences and engineering Waterloo · balance sheet 676,178 €
- A-membranes Research and experimental development on natural sciences and engineering Leuven · balance sheet 633,856 €
Frequently asked questions about Convert Pharmaceuticals
What is the revenue of Convert Pharmaceuticals?
Convert Pharmaceuticals files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Convert Pharmaceuticals?
In Belgium, the VAT number is the company number prefixed with BE: BE0671828631 for Convert Pharmaceuticals, if the company is VAT-registered. Its company number (CBE) is 0671.828.631.
Where is the registered office of Convert Pharmaceuticals?
According to the CBE register, the registered office of Convert Pharmaceuticals is in 4000 Liège.
What is the equity of Convert Pharmaceuticals?
At the close of the 2025 financial year, the equity of Convert Pharmaceuticals amounts to -841,823 €, a solvency of -89.4% of total assets.
Who manages Convert Pharmaceuticals?
The register lists 5 active mandates at Convert Pharmaceuticals. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Convert Pharmaceuticals
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →